|
1
|
Zeinoun Z, Teugels E, De Bleser PJ, Neyns
B, Geerts A and De Greve J: Insufficient TGF-beta 1 production
inactivates the autocrine growth suppressive circuit in human
ovarian cancer cell lines. Anticancer Res. 19:413–420.
1999.PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spentzos D, Levine DA, Ramoni MF, Joseph
M, Gu X, Boyd J, Libermann TA and Cannistra SA: Gene expression
signature with independent prognostic significance in epithelial
ovarian cancer. J Clin Oncol. 22:4700–4710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berchuck A, Iversen ES, Lancaster JM,
Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M,
et al: Patterns of gene expression that characterize long-term
survival in advanced stage serous ovarian cancers. Clin Cancer Res.
11:3686–3696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartmann LC, Lu KH, Linette GP, Cliby WA,
Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, et
al: Gene expression profiles predict early relapse in ovarian
cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res.
11:2149–2155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spentzos D, Levine DA, Kolia S, Otu H,
Boyd J, Libermann TA and Cannistra SA: Unique gene expression
profile based on pathologic response in epithelial ovarian cancer.
J Clin Oncol. 23:7911–7918. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Helleman J, Jansen MP, Span PN, van
Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC,
van der Burg ME, Stoter G, et al: Molecular profiling of platinum
resistant ovarian cancer. Int J Cancer. 118:1963–1971. 2006.
View Article : Google Scholar
|
|
9
|
Dressman HK, Berchuck A, Chan G, Zhai J,
Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, et al: An
integrated genomic-based approach to individualized treatment of
patients with advanced-stage ovarian cancer. J Clin Oncol.
25:517–525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crijns AP, Fehrmann RS, de Jong S, Gerbens
F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de
Vries EG, et al: Survival-related profile, pathways, and
transcription factors in ovarian cancer. PLoS Med. 6:e242009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flamant L, Roegiers E, Pierre M, Hayez A,
Sterpin C, De Backer O, Arnould T, Poumay Y and Michiels C: TMEM45A
is essential for hypoxia-induced chemoresistance in breast and
liver cancer cells. BMC Cancer. 12:3912012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urquidi V, Goodison S, Cai Y, Sun Y and
Rosser CJ: A candidate molecular biomarker panel for the detection
of bladder cancer. Cancer Epidemiol Biomarkers Prev. 21:2149–2158.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jinawath N, Chamgramol Y, Furukawa Y,
Obama K, Tsunoda T, Sripa B, Pairojkul C and Nakamura Y: Comparison
of gene expression profiles between Opisthorchis viverrini and
non-Opisthorchis viverrini associated human intrahepatic
chol-angiocarcinoma. Hepatology. 44:1025–1038. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsieh TC and Wu JM: Differential control
of growth, cell cycle progression, and gene expression in human
estrogen receptor positive MCF-7 breast cancer cells by extracts
derived from polysaccharopeptide I’m-Yunity and Danshen and their
combination. Int J Oncol. 29:1215–1222. 2006.PubMed/NCBI
|
|
15
|
Subramanian A, Kuehn H, Gould J, Tamayo P
and Mesirov JP: GSEA-P: a desktop application for gene set
enrichment analysis. Bioinformatics. 23:3251–3253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Silletti S, Paku S and Raz A: Autocrine
motility factor and the extracellular matrix. I coordinate
regulation of melanoma cell adhesion, spreading and migration
involves focal contact reorganization. Int J Cancer. 76:120–128.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wakefield LM and Roberts AB: TGF-beta
signaling: Positive and negative effects on tumorigenesis. Curr
Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vergara D, Merlot B, Lucot JP, Collinet P,
Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal
transition in ovarian cancer. Cancer Lett. 291:59–66. 2010.
View Article : Google Scholar
|
|
22
|
Schmitz AA, Govek EE, Böttner B and Van
Aelst L: Rho GTPases: signaling, migration, and invasion. Exp Cell
Res. 261:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aznar S and Lacal JC: Rho signals to cell
growth and apoptosis. Cancer Lett. 165:1–10. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fritz G, Just I and Kaina B: Rho GTPases
are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abraham MT, Kuriakose MA, Sacks PG, Yee H,
Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins
as markers for head and neck squamous cell cancer. Laryngoscope.
111:1285–1289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kamai T, Arai K, Tsujii T, Honda M and
Yoshida K: Over-expression of RhoA mRNA is associated with advanced
stage in testicular germ cell tumour. BJU Int. 87:227–231. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Horiuchi A, Imai T, Wang C, Ohira S, Feng
Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA
and RhoC, is associated with tumor progression in ovarian
carcinoma. Lab Inves. 83:861–870. 2003. View Article : Google Scholar
|
|
28
|
Kamai T, Tsujii T, Arai K, Takagi K, Asami
H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway
with invasion and metastasis of bladder cancer. Clin Cancer Res.
9:2632–2641. 2003.PubMed/NCBI
|
|
29
|
Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y,
Yao X, Zheng Y and Fan D: Reversal of the malignant phenotype of
gastric cancer cells by inhibition of RhoA expression and activity.
Clin Cancer Res. 10:6239–6247. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pille JY, Denoyelle C, Varet J, Bertrand
JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, et
al: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and
invasiveness of MDA-MB-231 breast cancer cells in vitro and in
vivo. Mol Ther. 11:267–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vigil D, Kim TY, Plachco A, Garton AJ,
Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL, et
al: ROCK1 and ROCK2 are required for non-small cell lung cancer
anchorage-independent growth and invasion. Cancer Res.
72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI
|
